Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Immunic Inc’s stock clocked out at $1.09, down -5.22% from its previous closing price of $1.15. In other words, the price has decreased by -$5.22 from its previous closing price. On the day, 0.78 million shares were traded.
Ratios:
To gain a deeper understanding of IMUX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.71 and its Current Ratio is at 2.71. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on November 25, 2024, initiated with a Buy rating and assigned the stock a target price of $10.
On August 27, 2024, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $6.B. Riley Securities initiated its Buy rating on August 27, 2024, with a $6 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 12 ’24 when Rudick Richard Alan bought 87,300 shares for $1.15 per share. The transaction valued at 100,369 led to the insider holds 87,300 shares of the business.
Stock Price History:
Over the past 52 weeks, IMUX has reached a high of $2.11, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of the stock is 3.76%, while the 200-Day Moving Average is calculated to be -13.21%.
Shares Statistics:
A total of 90.08M shares are outstanding, with a floating share count of 87.36M. Insiders hold about 3.02% of the company’s shares, while institutions hold 57.18% stake in the company.
